Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 3;8(1):e002012. doi: 10.1136/rmdopen-2021-002012

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Mean change from baseline in HAQ-DI and pain at week 156 (LOCF). Nominal ^##p<0.01, ^###p<0.001 for upadacitinib plus MTX versus adalimumab plus MTX. Treatment groups are by initial randomisation. Observations after rescue were replaced with the last observation prior to rescue, and analysis was based on ANCOVA model with treatment and prior bDMARD use as fixed factors and bL value as covariate. HAQ-DI is rated on a 0–3 scale; patient’s assessment of pain is scored on a 0–100 mm scale. ADA, adalimumab; bDMARD, biological disease modifying antirheumatic drug; bL, baseline; EOW, every other week; HAQ-DI, Health Assessment Questionnaire-Disability Index; LOCF, last observation carried forward; LS, least squares; MTX, methotrexate; QD, once daily; UPA, upadacitinib.